LONDON–(BUSINESS WIRE)–#Biotechnology–The global HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors market is expected to post a CAGR close to 9% during the period 2019-2023, according to the latest market research report by Technavio. Request a free sample report
Usually, HER2 regulates cell growth, survival, and differentiation through multiple signal transduction pathways. It also contributes to cellular proliferation and differentiation. However, the overexpression of HER2 causes several cancers, including breast cancer, gastric cancer, and ovarian cancer. For instance, the amplification or overexpression of HER2 occurs in approximately 16-30% of the breast cancer cases and 10-30% of the gastric cancer cases. Therefore, the high prevalence of HER2-related cancers, including breast cancer and gastric cancer, is expected to increase the demand for HER2 inhibitors during the forecast period.
Looking for more information on this market? Request a free sample report
As per Technavio, patient assistance programs, will have a positive impact on the market and contribute to its growth significantly over the forecast period. This research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.
Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market 2019-2023: Patient Assistance Programs
Currently, pharmaceutical sponsors are providing several patient assistance programs to reduce the cost burden on patients. For instance, Roche is providing several patient assistance programs, such as Herceptin Access Solutions and PERJETA Financial Assistance, for Herceptin and other oncology drugs. Similarly, Pfizer has introduced Pfizer Oncology Together, a program that offers personalized support to patients. With this program, eligible, commercially insured patients do not have to pay for VIZIMPRO. Such patient assistance programs will increase patient adherence to HER2 inhibitors, which will drive the growth of the market during the forecast period.
“Apart from patient assistance programs, the introduction of new diagnostics for breast cancer and strategic alliances are some other factors that will drive market growth during the forecast period.,” says a senior analyst at Technavio.
Global HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market 2019-2023: Segmentation Analysis
This market research report segments the global HER2 (human epidermal growth factor receptor 2) inhibitors market by product (monotherapy and combination therapy) and geographical regions (North America, Europe, Asia, and ROW).
The North American region led the market in 2018, followed by Europe, Asia, and ROW, respectively. During the forecast period, the North American region and Asian region are expected to register the highest incremental growth due to the increase in the sale of approved HER2 inhibitors owing to the high prevalence of breast cancer.
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Some of the key topics covered in the report include:
Market Landscape
- Market ecosystem
- Market characteristics
- Market segmentation analysis
Market Sizing
- Market definition
- Market size and forecast
Five Forces Analysis
Market Segmentation
Geographical Segmentation
- Regional comparison
- Key leading countries
Market Drivers
Market Challenges
Market Trends
Vendor Landscape
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com